{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:08:01Z","timestamp":1761102481795,"version":"3.37.3"},"reference-count":26,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.2217\/fon-2021-1176","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T14:15:16Z","timestamp":1637158516000},"page":"553-564","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Outcomes of Pomalidomide Therapy after Lenalidomide Induction in Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-0497","authenticated-orcid":false,"given":"Tomer","family":"Mark","sequence":"first","affiliation":[{"name":"University of Colorado Denver-Anschutz Medical Campus,\rAurora,\rCO,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Falkenstein","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions,\r7000 Cardinal Place,\rDublin,\rOH,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-8468","authenticated-orcid":false,"given":"Jonathan","family":"Kish","sequence":"additional","affiliation":[{"name":"Cardinal Health Specialty Solutions,\r7000 Cardinal Place,\rDublin,\rOH,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"e_1_3_6_3_1","article-title":"Surveillance, Epidemiology, and End Results (SEER) Program","author":"National Cancer Institute","year":"2018","unstructured":"National Cancer Institute . Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Myeloma (2014\u20132018)(2018). https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html","journal-title":"Cancer Stat Facts: Myeloma (2014\u20132018)"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0057"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2586"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-795047"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113125"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0813-1"},{"issue":"9","key":"e_1_3_6_14_1","first-page":"3643","article-title":"The genetic origin of drug resistance in neoplasms: implications for systemic therapy","volume":"44","author":"Goldie JH","year":"1984","unstructured":"Goldie JH , ColdmanAJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res.44(9), 3643\u20133653 (1984).","journal-title":"Cancer Res."},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.119"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.66"},{"key":"e_1_3_6_17_1","unstructured":"Celgene Corporation\n. POMALYST \u00ae (pomalidomide) [package insert] (2020). https:\/\/packageinserts.bms.com\/pi\/pi_pomalyst.pdf"},{"key":"e_1_3_6_18_1","unstructured":"Bristol Myers Squibb\n. REVLIMID \u00ae (lenalidomide) [package insert] (2020). https:\/\/packageinserts.bms.com\/pi\/pi_revlimid.pdf"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.238"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-611426"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13905"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16213"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1781"},{"key":"e_1_3_6_24_1","unstructured":"Bristol-Myers Squibb Company\n. U.S. Food and Drug Administration approves Empliciti \u00ae (elotuzumab) plus pomalidomide and dexamethasone a new immunotherapy combination for certain patients with relapsed or refractory multiple myeloma (2018). https:\/\/news.bms.com\/news\/details\/2018\/US-Food-and-Drug-Administration-Approves-Empliciti-elotuzumab-Plus-Pomalidomide-and-Dexamethasone-a-New-Immunotherapy-Combination-for-Certain-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma\/default.aspx"},{"key":"e_1_3_6_25_1","unstructured":"U.S. Food and Drug Administration\n. FDA approves isatuximab-irfc for multiple myeloma (2020). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-isatuximab-irfc-multiple-myeloma-0"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19337"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.444"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00228"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-1176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:12Z","timestamp":1719124992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-1176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.2217\/fon-2021-1176"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-1176","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}